Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc
Your view on AVDL
Overview
What the company does, where it operates, and who runs it.
About Avadel Pharmaceuticals plc
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Gregory J. Divis Jr.
- Headquarters
- 10 Earlsfort Terrace, Dublin, IE
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Gregory J. Divis Jr.
- Headquarters
- 10 Earlsfort Terrace, Dublin, IE
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Avadel Pharmaceuticals plc, and the rating behind it. AVDL last traded at $21.64; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Avadel Pharmaceuticals plc. Starting points for Avadel Pharmaceuticals plc: EPS -$0.02, beta 1.31 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Avadel Pharmaceuticals plc. Trailing twelve-month EPS for Avadel Pharmaceuticals plc stands at -$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Avadel Pharmaceuticals plc valued side by side against its closest peers. Avadel Pharmaceuticals plc is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Avadel Pharmaceuticals plc, and how their positions are changing. At a $2.12B market value, institutional positions materially move Avadel Pharmaceuticals plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Avadel Pharmaceuticals plc executives and directors. Shares of Avadel Pharmaceuticals plc have traded between $6.38 and $23.57 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc is a $2.12B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Avadel Pharmaceuticals plc. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Avadel Pharmaceuticals plc. Coverage tracks Avadel Pharmaceuticals plc within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.